Skip to main content
. Author manuscript; available in PMC: 2022 Sep 1.
Published in final edited form as: Blood Rev. 2021 Mar 16;49:100825. doi: 10.1016/j.blre.2021.100825

Table 1.

Treatment response milestones as defined by the NCCN guidelines. If resistance is suspected (possible resistance), the physician has the option of increasing imatinib to 800 mg, switching to a different TKI or continuing the same 2G TKI. Switching to an alternate TKI is recommended for TKI resistant disease.

BCR-ABL1 (IS) 3 months 6 months 12 months
>10% Possible Resistance Resistance
>1–10% TKI-sensitive Possible Resistance
>0.1–1% TKI-sensitive TKI-sensitive*
<0.1% TKI-sensitive
*

Shared decision making: consider switching to an alternate TKI to increase the chances for TFR.